BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18843024)

  • 21. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
    Lin YL; Sun G; Liu XQ; Li WP; Ma JG
    J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.
    Brait M; Maldonado L; Noordhuis MG; Begum S; Loyo M; Poeta ML; Barbosa A; Fazio VM; Angioli R; Rabitti C; Marchionni L; de Graeff P; van der Zee AG; Wisman GB; Sidransky D; Hoque MO
    PLoS One; 2013; 8(9):e70878. PubMed ID: 24086249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling.
    Kim YJ; Yoon HY; Kim JS; Kang HW; Min BD; Kim SK; Ha YS; Kim IY; Ryu KH; Lee SC; Kim WJ
    Int J Cancer; 2013 Sep; 133(5):1135-42. PubMed ID: 23436614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.
    Parrella P; Poeta ML; Gallo AP; Prencipe M; Scintu M; Apicella A; Rossiello R; Liguoro G; Seripa D; Gravina C; Rabitti C; Rinaldi M; Nicol T; Tommasi S; Paradiso A; Schittulli F; Altomare V; Fazio VM
    Clin Cancer Res; 2004 Aug; 10(16):5349-54. PubMed ID: 15328171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
    J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
    Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
    Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of PMF1 methylation in association with bladder cancer progression.
    Aleman A; Cebrian V; Alvarez M; Lopez V; Orenes E; Lopez-Serra L; Algaba F; Bellmunt J; López-Beltrán A; Gonzalez-Peramato P; Cordon-Cardo C; García J; del Muro JG; Esteller M; Sánchez-Carbayo M
    Clin Cancer Res; 2008 Dec; 14(24):8236-43. PubMed ID: 19088041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
    Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
    J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
    Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
    Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors.
    García-Baquero R; Puerta P; Beltran M; Alvarez-Mújica M; Alvarez-Ossorio JL; Sánchez-Carbayo M
    Tumour Biol; 2014 Jun; 35(6):5777-86. PubMed ID: 24577895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.